Gynecologic Cancers | Topics

 
Paclitaxel Plus Carboplatin Is Reportedly Non-Interior to Paclitaxel and Ifosfamide in Uterine Carcinosarcoma
January 13, 2022

Findings from a phase 3 study indicated that patients with uterine carcinosarcoma treated with paclitaxel and carboplatin experienced a better progression-free survival and non-inferior duration of overall survival vs paclitaxel plus ifosfamide.

Second-Line Balstilimab Plus Zalifrelimab Yields Durable Clinical Activity in Recurrent/Metastatic Cervical Cancer
January 07, 2022

Findings from a phase 2 study demonstrated encouraging clinical activity and a manageable safety profile when patients with advanced cervical cancer were treated with second-line balstilimab and zalifrelimab.

Tamoxifen for Primary Breast Cancer May Increase PI3K Signaling and Secondary Uterine Cancer Risk
December 07, 2021

Treatment with tamoxifen for primary breast cancer may result in increased risk of developing subsequent uterine cancer by activating the PI3K pathway.

Loop Electrosurgical Excision Procedure for HIV+ Women More Likely to Clear High-Risk HPV Infection vs Cryotherapy for CIN
November 26, 2021

A secondary analysis of a clinical trial indicated that women who were human immunodeficiency virus–positive and underwent loop electrosurgical excision procedure for cervical intraepithelial neoplasia had an increased likelihood of clearing high-risk human papillomavirus than women who underwent cryotherapy.

Camrelizumab/Apatinib Combo May Be Promising as Salvage Therapy for High-Risk Chemorefractory or Relapsed Gestational Trophoblastic Neoplasia
November 04, 2021

Camrelizumab plus apatinib demonstrated efficacious anti-tumor activity and could be a worthwhile salvage therapy in high-risk chemorefractory or relapsed gestational trophoblastic neoplasia.

FDA Approves First-Line Pembrolizumab Plus Chemo With or Without Bevacizumab for Cervical Cancer
October 13, 2021

The FDA has approved the use of pembrolizumab plus chemotherapy with or without bevacizumab in patients with persistent, recurrent, or metastatic cervical cancer who have PD-L1 expression identified via an FDA-approved test.

Risk-Reducing Salpingectomy Yields Higher QoL for BRCA1/2 Pathogenic Variant Carriers With Gynecologic Cancer
September 14, 2021

Patients who were carriers of pathogenic variants of for BRCA1/2 had a better physical and mental quality of life after undergoing risk-reducing salpingectomy compared with risk-reducing salpingo-oophorectomy.

Total Abdominal Hysterectomy Plus Chemo Yields Improved Survival Over Chemo Alone in Newly Diagnosed Uterine Cancer With Distant Metastasis
August 25, 2021

Women who received a total abdominal hysterectomy plus chemotherapy showed better survival then those women who received chemotherapy alone for uterine cancer with distant organ metastasis.

Financial Toxicity May Lead to Cost-Coping Strategies in Gynecologic Cancer
August 12, 2021

Use of economic coping mechanisms were associated with scoring 26 or lower on the COST analysis, or Comprehensive Score for Financial Toxicity, in patients being treated for gynecologic cancers.

FDA Accepts for Review Supplemental Biologics License of Pembrolizumab for MSI-H/dMMR Advanced Endometrial Cancer
August 10, 2021

The phase 2 KEYNOTE-158 trial has demonstrated promising responses in patients with microsatellite instability–high/ mismatch repair deficient advanced endometrial carcinoma, and led to the FDA accepting a review of a new supplemental biologics license application for the drug.